Related Experiment Video
Updated: Apr 23, 2026
Author Spotlight: Developing a Rat Model for Weight-Bearing Intervention to Investigate Osteonecrosis of the Femoral Head
Published on: September 27, 2024
Protective effects of necrostatin-1 on glucocorticoid-induced osteoporosis in rats
Min Feng1, RuiRui Zhang2, Futai Gong3
1Department of Orthopaedics, Second Affiliated Hospital of Xi'an Jiaotong University No.157 Xiwu Road, Xi'an, Shaanxi Province, PR China.
Abstract:
The inhibition of bone formation has been suggested to play a central role in the pathogenesis of glucocorticoid-induced osteoporosis (GIOP). Recently, many studies suggested that there may be another mechanism involved in GIOP besides apoptosis. The aim of this study was to investigate the protective effect of Necrostatin-1 on GIOP rats. Forty male Sprague-Dawley rats were randomly divided into four groups (n=10): controls; GIOP rats; GIOP rats pretreated with alendronate; and GIOP rats pretreated with Necrostatin-1. Their bone mineral density (BMD) and body weight were measured at the beginning and at the end of the experiment. TUNEL assay, transmission electron microscopy (TEM) and scanning electron microscopy (SEM) were used to observe the change of cellular morphology induced by Nec-1. The biochemical analysis and histomorphometric analysis were used to evaluate the change of bone formation by Nec-1. RIP-1, RIP-3 and caspase-8 expression were evaluated by immunohistochemistry. We found more TUNEL positive osteocytes and larger lacunae volume in GIOP rats compared with the control group. However, most of the osteocytes displayed a necrotic morphology and mitochondria lesions under TEM. In contrast to alendronate, Necrostatin-1 significantly elevated the level of bone formation markers, while it had no effect on bone resorption markers. Necrostatin-1 also markedly ameliorated trabecular bone. In addition, Necrostatin-1 significantly weaken the immunoreactivity of RIP-1 in GIOP rats while had no effect on RIP-3 and caspase-8. These data suggest, for the first time, that Necrostatin-1 accelerate bone formation of glucocorticoid-induced osteoporosis in rats.
Insights
Necrostatin-1 was found to accelerate bone formation in rats with glucocorticoid-induced osteoporosis (GIOP). This compound improved bone structure by enhancing osteocyte health and promoting bone formation, offering a new therapeutic avenue for GIOP.
Area of Science:
- Biomedical Sciences
- Osteoporosis Research
- Cellular Biology
Background:
- Glucocorticoid-induced osteoporosis (GIOP) is linked to inhibited bone formation.
- Apoptosis is a known factor in GIOP, but other mechanisms may be involved.
- Necrostatin-1 is investigated for its potential protective effects in GIOP.
Purpose of the Study:
- To investigate the protective effect of Necrostatin-1 on GIOP rats.
- To evaluate Necrostatin-1's impact on bone formation and resorption markers.
- To assess Necrostatin-1's influence on osteocyte morphology and survival.
Main Methods:
- Forty male Sprague-Dawley rats were divided into control, GIOP, alendronate-treated GIOP, and Necrostatin-1-treated GIOP groups.
- Bone mineral density (BMD), body weight, cellular morphology (TUNEL, TEM, SEM), bone formation/resorption markers, and protein expression (RIP-1, RIP-3, caspase-8) were analyzed.
- Immunohistochemistry was used to evaluate RIP-1, RIP-3, and caspase-8 expression.
Main Results:
- GIOP rats showed increased TUNEL-positive osteocytes and lacunae volume, with necrotic morphology and mitochondrial damage.
- Necrostatin-1 significantly increased bone formation markers without affecting bone resorption markers.
- Necrostatin-1 treatment ameliorated trabecular bone structure and reduced RIP-1 immunoreactivity.
Conclusions:
- Necrostatin-1 demonstrates a protective effect in GIOP rats by promoting bone formation.
- The mechanism involves enhancing osteocyte health and potentially modulating RIP-1 signaling.
- Necrostatin-1 represents a potential therapeutic agent for glucocorticoid-induced osteoporosis.
